TYK2 and non-Hodgkin lymphoma: In addition to the increased infection risk, there is a potential risk of lung cancer, non-Hodgkin lymphoma, and reduced β-cell mass with TYK2 inhibition35,67, indicating that further safety assessments will be needed for long-term treatment with TYK2 inhibitors.